X

Sterling Biotech Ltd Stock Analysis

Small Cap
Evaluated by 445 users | BSE: 512299 | NSE: STERLINBIO |
Chemicals
Sterling Biotech incorporated in 1985, is engaged in manufacturing of pharmaceutical and nutraceutical gelatin. Company manufactures two kinds of gelatin namely pharmaceutical and edible. Sterling Biotech is promoted by Vadodara-based Rs 23,000 crore Sandesara group.In the year 1995, company...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Mar'16Mar'17Mar'18
Return on Capital Employed 7%6.2%6.17%4.26%-0.98%-1.74%-2.07%-2.08%-1.87%-1.96%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 1,1781,4381,6171,662835718667419368352
Y-o-Y Gr. Rt.-22.1%12.4%2.8%-49.8%-14%-7.1%-37.2%-12.1%-4.4%
Adjusted EPS (Rs.) 9.227.677.073.23-13.03-14.96-16.82-13.24-15.15-17.08
Y-o-Y Gr. Rt.--16.8%-7.8%-54.3%-503.4%NANANANANA
Book Value per Share (Rs.) 69.8982.1992.0292.9969.8454.8838.1448.946.8910.14
Adjusted Net Profit 22819219086.5-349-401-458-360-412-465
Net Op. Cash Flow (Rs. Cr.) -98.7-1.334837081117225653.61-32.8
Debt to Cash Flow from Ops -27.05-2,339.6210.7511.514.4822.5917.9797.987,326.31-228.39
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Sterling Biotech Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -12.6%-15.9%-19.2%-4.4%
Adjusted EPS -207.1%NANANA
Book Value per Share -19.3-32-35.7-78.4
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Mar'16Mar'17Mar'18
Return on Equity (%) 15.1110.18.353.49-16-23.98-22.8-21.41-28.06-59.9
Operating Profit Margin (%) 42.5435.1543.1238.3517.6813.1911.9812.33.414
Net Profit Margin (%) 19.3613.3411.725.2-41.8-55.8-68.63-85.97-111.95-131.91
Debt to Equity 1.571.51.521.711.942.641.813.955.4527.16
Working Capital Days 3053764214588017427247911,097853
Cash Conversion Cycle 187232271325630586524504669427
Entity Percentage Holding
Promoters 24.64%
Institutions 21.93%
Non-Institutions 53.43%
Pledged *62.2962.2962.2962.2962.2962.2962.2962.2962.2962.29
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Sterling Biotech incorporated in 1985, is engaged in manufacturing of pharmaceutical and nutraceutical gelatin. Company manufactures two kinds of gelatin namely pharmaceutical and edible. Sterling Biotech is promoted by Vadodara-based Rs 23,000 crore Sandesara group.

In the year 1995, company entered into an agreement with CRODA Colloids of UK, a world leader in Gelatin technology, to set up brand new Gelatin manufacturing facility in Read More

Sterling Biotech incorporated in 1985, is engaged in manufacturing of pharmaceutical and nutraceutical gelatin. Company manufactures two kinds of gelatin namely pharmaceutical and edible. Sterling Biotech is promoted by Vadodara-based Rs 23,000 crore Sandesara group.

In the year 1995, company entered into an agreement with CRODA Colloids of UK, a world leader in Gelatin technology, to set up brand new Gelatin manufacturing facility in India

Gelatin contains 80-90% protein and is not only used extensively in the pharmaceutical, food and photographic industry, but also in such diverse industries as cosmetics, metal refining, paper, plastics and toiletries. It is also used by food industry in area of sugars, starches, gums, seasonings, colours and flavourings. 

The company is largest producer of pharmaceutical and nutraceutical gelatin in India and Asia as well. It has a 9.3% global market share in pharmaceutical gelatin and is among the top five gelatin producers globally.

Further, Sterling sells Dicalcium Phosphate (DCP), which a by-product generated during gelatin manufacturing process, to poultry-feed and fertilizer industry in India. DCP is used in manufacturing of products such as talcum powder, fertilizers and toothpaste.

Company operates state-of-the-art facilities which well equipped with technology, is located at Vadodara and Ooty. Company also operates a captive Heavy Fuel Oil (HFO) based power plant based to minimise its power cost and become self sufficient in its power requirements.

Company has received various quality certifications such as HACCP (Hazardous Analysis and Critical Control Point) certification that certifies the manufacturing process with the highest and most consistent quality and safety of product; ISO 9001 and ISO 14001 for its production process and EDQM (European Directorate for Quality of Medicare) - this certification denotes that the product is in compliance with the European Union pharmacopeia.

Company has also received recognition as One Star Export House. Company is amongst low cost producer of gelatin in the world.

Outlook

Sterling Biotech will continue to put its efforts in the areas of product quality, process improvement technology with the aim of offering better products to meet consumer needs.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback